These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 10792847)

  • 41. Distribution of pertussis antibodies among different age groups in Japan.
    Konda T; Kamachi K; Iwaki M; Matsunaga Y
    Vaccine; 2002 Mar; 20(13-14):1711-7. PubMed ID: 11906757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
    Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
    Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sero epidemiology of Bordetella pertussis immune responses in a healthy population in northern Greece.
    Polyzou A; Pournaras S; Dafni U; Sofianou D; Christeli E; Patrinos S; Tsakris A
    J Clin Lab Anal; 2004; 18(3):211-4. PubMed ID: 15103688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
    Thomas MG; Ashworth LA; Miller E; Lambert HP
    J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge.
    Canthaboo C; Xing D; Wei XQ; Corbel MJ
    Infect Immun; 2002 Feb; 70(2):679-84. PubMed ID: 11796599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crucial role of antibodies to pertactin in Bordetella pertussis immunity.
    Hellwig SM; Rodriguez ME; Berbers GA; van de Winkel JG; Mooi FR
    J Infect Dis; 2003 Sep; 188(5):738-42. PubMed ID: 12934190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.
    Conway MA; Madrigal-Estebas L; McClean S; Brayden DJ; Mills KH
    Vaccine; 2001 Feb; 19(15-16):1940-50. PubMed ID: 11228364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.
    Ohman L; Willén R; Hultgren OH; Hultgren Hörnquist E
    Clin Exp Immunol; 2005 Jul; 141(1):37-46. PubMed ID: 15958068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A recombinant iron transport protein from Bordetella pertussis confers protection against Bordetella parapertussis.
    Alvarez Hayes J; Oviedo JM; Valdez H; Laborde JM; Maschi F; Ayala M; Shah R; Fernandez Lahore M; Rodriguez ME
    Microbiol Immunol; 2017 Oct; 61(10):407-415. PubMed ID: 28857261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen.
    Hijnen M; Mooi FR; van Gageldonk PG; Hoogerhout P; King AJ; Berbers GA
    Infect Immun; 2004 Jul; 72(7):3716-23. PubMed ID: 15213111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bordetella parapertussis infections.
    Mastrantonio P; Giuliano M; Stefanelli P; Sofia T; De Marzi L; Tarabini G; Quarto M; Moiraghi A
    Dev Biol Stand; 1997; 89():255-9. PubMed ID: 9272358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
    Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
    J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibodies produced against a fragment of filamentous haemagglutinin (FHA) of Bordetella pertussis are able to inhibit hemagglutination induced by the whole adhesin.
    Colombi D; Horton DS; Oliveira ML; Sakauchi MA; Ho PL
    FEMS Microbiol Lett; 2004 Nov; 240(1):41-7. PubMed ID: 15500977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.
    Berstad AKH; Holst J; Frøholm LO; Haugen IL; Wedege E; Oftung F; Haneberg B
    J Med Microbiol; 2000 Feb; 49(2):157-163. PubMed ID: 10670566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Humoral reaction to Bordetella pertussis antigens: pertussis toxin, filamentous hemagglutinin and lipopolysaccharide in children with clinical symptoms of whooping cough. II. Occurence and level of B. pertussis antigens in children with suspected whooping cough].
    Chodorowska M
    Med Dosw Mikrobiol; 1999; 51(3-4):269-80. PubMed ID: 10803256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum antibodies against a 69-kilodalton outer-membrane protein, pertactin, from Bordetella pertussis in nonvaccinated children with and without a history of clinical pertussis.
    Trollfors B; Zackrisson G; Taranger J; Lagergård T
    J Pediatr; 1992 Jun; 120(6):924-6. PubMed ID: 1593352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
    Boros CA; Hanlon M; Gold MS; Roberton DM
    Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interaction of Bordetella pertussis filamentous hemagglutinin with human TLR2: identification of the TLR2-binding domain.
    Asgarian-Omran H; Amirzargar AA; Zeerleder S; Mahdavi M; van Mierlo G; Solati S; Jeddi-Tehrani M; Rabbani H; Aarden L; Shokri F
    APMIS; 2015 Feb; 123(2):156-62. PubMed ID: 25353353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.